Navigation Links
Oncolytics Biotech(R) Inc. Announces Exercise of Underwriters' Over-Allotment Option
Date:12/2/2009

CALGARY, Dec. 2 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. ("Oncolytics" or the "Company") (TSX:ONC; NASDAQ:ONCY) announced today that in connection with its previously announced unit offering, the underwriters have exercised in full their over-allotment option and purchased an additional 637,500 units. Each unit is comprised of one common share and 0.4 of a common share purchase warrant, and was sold at a price of US$3.00 per unit. Each whole common share purchase warrant entitles the holder to acquire one common share of Oncolytics upon payment of US$3.50 for a five year period ending November 23, 2014, subject to an acceleration of the expiry date in certain circumstances. Oppenheimer & Co. Inc. acted as the sole book-running manager for the offering. Canaccord Capital Corporation and Bloom Burton & Co. acted as Canadian co-managers for the offering.

Together with the units sold on November 23, 2009, the Company has issued an aggregate of 4,887,500 units consisting of 4,887,500 common shares and 1,955,000 common share purchase warrants for total gross proceeds of US$14,662,500.

Oncolytics intends to use the net proceeds from the offering to fund its previously announced Phase III combination REOLYSIN(R) and paclitaxel/carboplatin trial for patients with platinum-failed head and neck cancers, its other clinical development and research and development activities, and for general corporate and working capital purposes.

"Completing this financing further strengthens our balance sheet and will allow us to proceed beyond the 80 patient first stage of enrollment in our Phase III clinical trial, while giving us improved flexibility in reviewing partnering options," said Dr. Brad Thompson, President and CEO of Oncolytics. "After giving effect to this financing, we have in excess of $36 million i
'/>"/>

SOURCE Oncolytics Biotech Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Oncolytics Biotech Inc. Announces Issuance of 23rd U.S. Patent
2. Oncolytics Biotech Inc. Reports Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial
3. Media Advisory - Oncolytics Biotech Inc. to Present at BioPartnering Europe
4. Media Advisory - Oncolytics Biotech Inc. to Present at BIO InvestorForum 2007
5. Oncolytics Biotech Inc. Announces Approval for U.K. Clinical Trial Investigating REOLYSIN(R) in Combination with Cyclophosphamide
6. Oncolytics Biotech Inc. Collaborators to Present Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial
7. Oncolytics Biotech Inc. Announces 2007 Third Quarter Results
8. Media Advisory - Oncolytics Biotech Inc. to Present at Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
9. Media Advisory - Oncolytics Biotech Inc. to Present at Toronto CFA Society
10. Oncolytics Biotech Inc. Announces Issuance of 24th U.S. Patent
11. Oncolytics Biotech Inc. to Present at Annual Vaccine Production Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/29/2014)... , Sept. 29, 2014  Ten of the ... of cartilage repair, regeneration, allograft reconstruction and research ... the world gathered to discuss the future of ... of Regenerative Medicine symposium, Cartilage Regeneration: State ... included Orthopedic Biosurgery, Minced Juvenile Allograft, and State ...
(Date:9/29/2014)... 29, 2014 Research and Markets  has ... Gas Analyzer, and Gas Chromatograph Market by Type , ... Global Trends & Forecast to 2013 - 2020" ... analyzer is a process analytical instrument that provides chemical ... redefined the way by which companies carry out their ...
(Date:9/29/2014)... NEW YORK , Sept. 29, 2014 /PRNewswire/ ... firm, and The Channel Group ("TCG"), a leader ... transition advisors, have formed an alliance to expand ... to prospective clients. With the alliance, Burnham Securities ... in the scientific, clinical medicine and management in ...
(Date:9/29/2014)... Israel , September 29, 2014 ... novel immunomodulators for severe infections, today announced that the ... has awarded Atox Bio with a contract valued up ... of AB103 to treat Necrotizing Soft Tissue Infections (NSTI) ... threats that end in sepsis. BARDA awarded ...
Breaking Biology Technology:World Renowned Experts Discuss Future Of Cartilage Regeneration 2World Renowned Experts Discuss Future Of Cartilage Regeneration 3Global Process Liquid Analyzer, Gas Analyzer, and Gas Chromatograph (PH/ORP, Chlorine, Oxygen, Carbon dioxide) Market - Trends & Forecast to 2020 2Global Process Liquid Analyzer, Gas Analyzer, and Gas Chromatograph (PH/ORP, Chlorine, Oxygen, Carbon dioxide) Market - Trends & Forecast to 2020 3Global Process Liquid Analyzer, Gas Analyzer, and Gas Chromatograph (PH/ORP, Chlorine, Oxygen, Carbon dioxide) Market - Trends & Forecast to 2020 4Burnham Securities Inc. and The Channel Group Form Healthcare Alliance 2Burnham Securities Inc. and The Channel Group Form Healthcare Alliance 3Atox Bio Awarded Contract Worth up to $24 Million for the Development of AB103 by the Biomedical Advanced Research and Development Authority (BARDA) 2
... MILWAUKEEThe growing popularity of digital music recorders, digital ... Brady Corporation 's recent acquisition of ID ... manufacturer and supplier of pressure sensitive die-cut components ... Brady Asia-Pacific Allan Klotsche, this acquisition, along with ...
... In order to surpass its original goal for life-long learning ... (ADL) Co-Laboratory has plans to move from University Research Park ... will make the move Sept. 1, a bit behind ... While delays in the approval processes are to blame for ...
... recently announced it received a Phase I small business ... Cancer Institute . , ,The grant, according to chief executive ... rapidly measure the activity of enzymes that are relevant to ... could develop a way to quickly quantify enzyme activity that ...
Cached Biology Technology:Brady continues growth through Asian acquisition 2Academic ADL Co-Lab moving to downtown Madison 2Academic ADL Co-Lab moving to downtown Madison 3
(Date:9/29/2014)... simple spheres of fluid, not normally considered capable of ... made droplets of alcohol move through water. In the ... able to move on your own to be ... organisms. But also non-living entities can be self-moving, report ... Chemical Technology in Prague, Czech Republic. , The researchers ...
(Date:9/29/2014)... This news release is available in French . ... 29th, 2014 - The number of days an expectant ... (1998) predicts the epigenetic profile of her child, a ... University Institute and McGill University have detected a distinctive ... aftermath of the massive Quebec ice storm. Five months ...
(Date:9/29/2014)... with Multiple Sclerosis (MS) were able to safely tolerate ... to a study published today in the journal ... is the first of its kind, was conducted by ... Celgene Corporation and collaborators at several other institutions. ... early signals in the data also suggested that a ...
Breaking Biology News(10 mins):Scientists make droplets move on their own 2Cells from placentas safe for patients with multiple sclerosis 2
... (Santa Barbara, Calif.) New research at UC Santa Barbara ... develop. The study is part of the campus,s expanding vision ... versions of The Proceedings of the National Academy of ... (IOVS). The scientists document how they used mice ...
... the collaboration of the Spanish Foundation for Biodiversity, the Charter ... the AZTI-Tecnalia R+D Centre will be studying the re-stocking of ... the months of May, June and July, respectively, in three ... gather the information needed to be able to manage the ...
... This release is available in German . ... research in Germany, the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) ... was taken by the appropriate Grants Committee in Bonn. The ... four and half years, during which time they will receive ...
Cached Biology News:UCSB scientists make strides in vision research 2A study will enable the survival and growth of the 3 development phases of the European eel 2DFG establishes 18 new research training groups 2DFG establishes 18 new research training groups 3DFG establishes 18 new research training groups 4DFG establishes 18 new research training groups 5DFG establishes 18 new research training groups 6DFG establishes 18 new research training groups 7DFG establishes 18 new research training groups 8DFG establishes 18 new research training groups 9DFG establishes 18 new research training groups 10
... were designed for full-length gene cloning and ... identify the desired cDNA clone. The first ... "Master Plate," where each well contains plasmid ... positive well(s) by gel electrophoresis of the ...
... Panels were designed for full-length gene cloning ... to identify the desired cDNA clone. The ... 96-well "Master Plate," where each well contains ... the positive well(s) by gel electrophoresis of ...
... Prepared by a modification of the ... Biotechnol. Bioeng., 11 , ... will yield an A 260 ... water (1 cm light path). Physical ...
... Dithiothreitol DTT White solid.. PACKAGED UNDER ... thiols, so reaction is "driven" to completion. A ... waxy surfactant found in many other preparations. Blocks ... Purity: ≥97% by titration. Contaminants: Heavy ...
Biology Products: